×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: TGG – WDE – PGF

Tim Boreham

Are These LICs Worth Buying?

July 26, 2018September 5, 2018 - by Tim Boreham

Growth stocks have outperformed value stocks in recent times, but the 31 year old value investor Templeton Growth Fund is a patient investor. Elsewhere in the listed investment company sector, a new fund is taking a different approach to ensure it doesn’t trade at a discount to asset backing.

Read More
  • Inauguration Inflation
  • Lunch Report: Aussie market bounces back
  • Optimistic Investing Belies an Uncertain Outlook
  • The Unknown Unknowns
  • Australia…One Hour In…ASX up 67 points
  • ELD – Citi rates the stock as Buy
  • SUL – Credit Suisse rates the stock as Outperform
  • CGF – Morgans rates the stock as Hold

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.